监测结直肠癌患者血清糖链抗原CA50的临床意义

THE CLINICAL SIGNIFICANCE OF MONITORING CARBOHYDRATE ANTIGEN CA50 IN PATIENTS WITH COLORECTAL CARCINOMA

为探讨ＣＡ５０在结直肠癌的诊断和术后监测方面的临床应用价值，应用免疫放射测定法（ＩＲＭＡ）对３０例健康人、６６例结直肠癌及２７例结直肠良性病患者血清ＣＡ５０水平进行了检测。结果：结直肠恶性肿瘤患者血清ＣＡ５０值显著高于良性病患者及健康人（Ｐ＜０．０１）；结直肠癌行根治手术后其血清ＣＡ５０含量较术前明显降低（Ｐ＜０．０１），术后复发者又再升高，而行姑息手术后其变化不显著（Ｐ＞０．０５）。

In order to investigate the possible involvement of the antigen CA50 in patients with colorectal carcinoma, the carbohydrated antigen CA50 in serum was examined in 30 normal individual, 27 patients with benign colorectal diseases and 66 patients with colorectal carcinoma by immunoradiometric assay (IRMA). The results showed that the serum CA50 in patients with colorectal carcinoma was significantly higher than that in patients with benign colorectal diseases and normal individual ( P <0.01). It was significantly declined after radical operation ( P <0.01). However, no significant change was noted after palliative operation ( P >0.05) and elevation was noted in patients with tumor recurrence. The results suggest that the measurement of serum CA50 may be an useful marker for diagnosis and prognostic evaluation in patients with colorectal carcinoma.